{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T12:36:24Z","timestamp":1788957384632,"version":"build-2803163510"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003769","name":"Eisai","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003769","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005614","name":"Biogen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005614","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","msard-journal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.msard.2021.103371","type":"journal-article","created":{"date-parts":[[2021,11,10]],"date-time":"2021-11-10T16:53:58Z","timestamp":1636563238000},"page":"103371","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["COVID-19 outcomes in persons with multiple sclerosis treated with rituximab"],"prefix":"10.1016","volume":"57","author":[{"given":"Rajesh B","family":"Iyer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raghavendra","family":"S","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javeria Nooraine","family":"M","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaychandran","family":"R","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.msard.2021.103371_bib0001","doi-asserted-by":"crossref","first-page":"e419","DOI":"10.1016\/S2665-9913(21)00059-X","article-title":"COVID-19 outcomes in patients with inflammatory rheumatic and musculoskeletal diseases treated with rituximab: a cohort study","volume":"3","author":"Avouac","year":"2021","journal-title":"Lancet Rheumatol."},{"key":"10.1016\/j.msard.2021.103371_bib0002","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1023\/A:1008416911099","article-title":"Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma","volume":"9","author":"Berinstein","year":"1998","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.msard.2021.103371_bib0003","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2021-220408","article-title":"SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response","author":"Bonelli","year":"2021","journal-title":"Ann. Rheum. Dis."},{"issue":"52","key":"10.1016\/j.msard.2021.103371_bib0004","article-title":"Reactivation of SARS-CoV-2 after rituximab in a patient with multiple sclerosis","volume":"25","author":"Bose","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2021.103371_bib0005","first-page":"1","article-title":"Rituximab for the treatment of multiple sclerosis: a review","volume":"8","author":"Chisari","year":"2021","journal-title":"J. Neurol."},{"issue":"8","key":"10.1016\/j.msard.2021.103371_bib0006","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1007\/s10072-020-04522-2","article-title":"Coronavirus disease 2019: favourable outcome in an immunosuppressed patient with multiple sclerosis","volume":"41","author":"Devogelaere","year":"2020","journal-title":"Neurol. Sci."},{"issue":"1","key":"10.1016\/j.msard.2021.103371_bib0007","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1186\/s12883-021-02218-4","article-title":"Rituximab and risk of COVID-19 infection and its severity in patients with MS and NMOSD","volume":"21","author":"Esmaeili","year":"2021","journal-title":"BMC Neurol."},{"issue":"9","key":"10.1016\/j.msard.2021.103371_bib0008","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1002\/art.41380","article-title":"Mild course of COVID-19 and spontaneous virus clearance in a patient with depleted peripheral blood B cells due to rituximab treatment","volume":"72","author":"Fallet","year":"2020","journal-title":"Arthritis Rheumatol."},{"issue":"1","key":"10.1016\/j.msard.2021.103371_bib0009","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1177\/1352458519868990","article-title":"Risk of secondary progressive multiple sclerosis: a longitudinal study","volume":"26","author":"Fambiatos","year":"2020","journal-title":"Mult. Scler."},{"issue":"2","key":"10.1016\/j.msard.2021.103371_bib0010","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1053\/j.seminhematol.2010.01.002","article-title":"Rituximab- associated infections","volume":"47","author":"Gea-Banacloche","year":"2010","journal-title":"Semin. Hematol."},{"issue":"7","key":"10.1016\/j.msard.2021.103371_bib0011","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1136\/annrheumdis-2020-217871","article-title":"COVID-19 Global Rheumatology Alliance. Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry","volume":"79","author":"Gianfrancesco","year":"2020","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.msard.2021.103371_bib0012","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1182\/asheducation-2005.1.321","article-title":"Multimodality therapies and optimal schedule of antibodies: rituximab in lymphoma as an example","author":"Ghielmini","year":"2005","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"issue":"2","key":"10.1016\/j.msard.2021.103371_bib0013","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s00467-018-4052-x","article-title":"Effect of different rituximab regimens on B cell depletion and time to relapse in children with steroid-dependent nephrotic syndrome","volume":"34","author":"Hogan","year":"2019","journal-title":"Pediatr. Nephrol."},{"issue":"4","key":"10.1016\/j.msard.2021.103371_bib0014","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1002\/acn3.51342","article-title":"Multiple sclerosis, rituximab, and COVID-19","volume":"8","author":"Langer-Gould","year":"2021","journal-title":"Ann. Clin. Transl. Neurol."},{"issue":"5","key":"10.1016\/j.msard.2021.103371_bib0015","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/j.semarthrit.2020.06.013","article-title":"Long, relapsing, and atypical symptomatic course of COVID-19 in a B-cell-depleted patient after rituximab","volume":"50","author":"Leipe","year":"2020","journal-title":"Semin. Arthritis Rheum."},{"issue":"9","key":"10.1016\/j.msard.2021.103371_bib0016","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1001\/jamaneurol.2020.2581","article-title":"Clinical characteristics and outcomes in patients with coronavirus disease 2019 and multiple sclerosis","volume":"77","author":"Louapre","year":"2020","journal-title":"JAMA Neurol."},{"issue":"2","key":"10.1016\/j.msard.2021.103371_bib0017","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1001\/jamaneurol.2019.3365","article-title":"Infection risks among patients with multiple sclerosis treated with fingolimod, natalizumab, rituximab, and injectable therapies","volume":"77","author":"Luna","year":"2020","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.msard.2021.103371_bib0018","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102306","article-title":"COVID-19 in 7 multiple sclerosis patients in treatment with ANTI-CD20 therapies","volume":"44","author":"Meca-Lallana","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"10","key":"10.1016\/j.msard.2021.103371_bib0019","doi-asserted-by":"crossref","first-page":"e589","DOI":"10.1016\/S2665-9913(20)30270-8","article-title":"B-cell depletion with rituximab in the COVID-19 pandemic: where do we stand?","volume":"2","author":"Mehta","year":"2020","journal-title":"Lancet Rheumatol."},{"key":"10.1016\/j.msard.2021.103371_bib0020","first-page":"1","article-title":"The prevalence of COVID-19 infection in patients with multiple sclerosis (MS): a systematic review and meta-analysis","volume":"7","author":"Moghadasi","year":"2021","journal-title":"Neurol. Sci."},{"issue":"12","key":"10.1016\/j.msard.2021.103371_bib0021","doi-asserted-by":"crossref","first-page":"4067","DOI":"10.3390\/jcm9124067","article-title":"Experience in multiple sclerosis patients with COVID-19 and disease-modifying therapies: a review of 873 published cases","volume":"16","author":"M\u00f6hn","year":"2020","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.msard.2021.103371_bib0022","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102185","article-title":"Anti-CD20 and COVID-19 in multiple sclerosis and related disorders: a case series of 60 patients from Madrid, Spain","volume":"42","author":"Montero-Escribano","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"10","key":"10.1016\/j.msard.2021.103371_bib0023","doi-asserted-by":"crossref","first-page":"9959","DOI":"10.18632\/aging.103344","article-title":"Why does COVID-19 disproportionately affect older people?","volume":"12","author":"Mueller","year":"2020","journal-title":"Aging (Albany NY)"},{"issue":"3","key":"10.1016\/j.msard.2021.103371_bib0024","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s40263-021-00804-1","article-title":"COVID-19 in patients with multiple sclerosis: associations with disease-modifying therapies","volume":"35","author":"Reder","year":"2021","journal-title":"CNS Drugs"},{"key":"10.1016\/j.msard.2021.103371_bib0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102472","article-title":"Evaluation of the rate of COVID-19 infection, hospitalization and death among Iranian patients with multiple sclerosis","volume":"46","author":"Sahraian","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2021.103371_bib0026","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.102800","article-title":"COVID-19 and disease-modifying therapies in patients with demyelinating diseases of the central nervous system: a systematic review","volume":"50","author":"Sharifian-Dorche","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"4","key":"10.1016\/j.msard.2021.103371_bib0027","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1002\/ana.26028","article-title":"Musc-19 Study Group. Disease-modifying therapies and coronavirus disease 2019 severity in multiple sclerosis","volume":"89","author":"Sormani","year":"2021","journal-title":"Ann. Neurol."},{"issue":"7","key":"10.1016\/j.msard.2021.103371_bib0028","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1136\/annrheumdis-2020-219498","article-title":"COVID-19 global rheumatology alliance. Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry","volume":"80","author":"Strangfeld","year":"2021","journal-title":"Ann. Rheum. Dis."},{"issue":"13","key":"10.1016\/j.msard.2021.103371_bib0029","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1001\/jama.2020.2648","article-title":"Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72\u00a0314 cases from the Chinese center for disease control and prevention","volume":"7","author":"Wu","year":"2020","journal-title":"JAMA"}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034821006386?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034821006386?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,30]],"date-time":"2024-12-30T16:36:00Z","timestamp":1735576560000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034821006386"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":29,"alternative-id":["S2211034821006386"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2021.103371","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"COVID-19 outcomes in persons with multiple sclerosis treated with rituximab","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2021.103371","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"103371"}}